NCT07244705 2025-11-24
A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC
Anbogen Therapeutics, Inc.
Phase 1/2 Recruiting
Anbogen Therapeutics, Inc.
Anaveon AG
Biomoda Inc.
Hebei Senlang Biotechnology Inc., Ltd.